Table 1 Patient characteristics
Study population | hEag1 positive | hEag1 | P-value | |
|---|---|---|---|---|
negative | ||||
No (%) | 118 | 47 (40) | 71 | |
Gender, no. of males (%) | 59 | 23 (50) | 36 | 1.0 |
Age, years median (range) | 49(1-89) | 60 (1-86) | 31 (1-89) | <0.001*** |
Age groups, N (%) | <0.001*** | |||
child (1-18 years) | 37 | 5 (13) | 32 | |
adult (19-59 years) | 38 | 18 (47) | 20 | |
elder (60-90 years) | 43 | 23 (53) | 20 | |
FAB classification, N (%) | 0.32 | |||
M0 | 7 | 2 (28) | 5 | |
M1 | 20 | 9 (45) | 11 | |
M2 | 25 | 14 (56) | 11 | |
M3 | 8 | 0 | 8 | |
M4 | 19 | 10 (53) | 9 | |
M4Eo | 6 | 0 | 6 | |
M5 | 14 | 3 (21) | 11 | |
M6 | 5 | 3 (60) | 2 | |
M7 | 3 | 1 (33) | 2 | |
unclassified | 11 | 5 (45) | 6 | |
Cytogenetic analysis, N (%) | 0.11 | |||
normal | 38 | 25 (66) | 13 | |
t (8;21) | 7 | 3 (43) | 4 | |
inv (16) | 6 | 0 | 6 | |
t (15;17) | 8 | 0 | 8 | |
11q23 abnormalities | 10 | 1 (10) | 9 | |
FLT3-ITD | 5 | 4 (80) | 1 | |
chromosome 5 or 7 abnormalities | 16 | 7 (44) | 9 | |
Trisomy 8 alone | 6 | 2 (33) | 4 | |
other single abnormality | 6 | 1 (17) | 5 | |
multiple abnormalities | 22 | 9 (41) | 13 | |
unknown | 14 | 4 | 10 | |
Cytogenetic classification, no. (%) | 0.66 | |||
Favorable | 16 | 3 (19) | 13 | |
Intermediate | 49 | 25 (51) | 24 | |
Unfavorable | 47 | 17 (36) | 30 | |
Unknown | 7 | 1 | 6 | |
Stem cell transplantation | 22 | 5 (23) | 17 | 0.29 |
No stem cell transplantation | 55 | 19 (34) | 36 | |
unknown | 41 | 22 | 19 | |
CR1 achieved, no. (%) | 0.94 | |||
achieved | 38 | 13 (34) | 25 | |
not achieved | 27 | 9 (33) | 18 | |
unknown | 53 | 24 | 29 | |
Relapse, no. (%) | 0.41 | |||
early relapse (within 6 months) | 10 | 5 (50) | 5 | |
late relapse | 32 | 11 (34) | 21 | |
no relapse within 3 years | 25 | 3 (12) | 22 | |
unknown | 24 | 13 | 11 | |
Death, no. (%) | 0.64 | |||
early death (within 6 months) | 26 | 13 (50) | 13 | |
late death | 32 | 14 (44) | 18 | |
Disease free survival (patient no.) | 99 | 37 | 62 | 0.0023*** |
median, months | 14 | 7 | 22 | |
disease free at 3 years, no. (%) | 28 | 5 (13) | 23 (37) | |
Overall survival (patient no.) | 99 | 37 | 62 | 0.0019*** |
median, months | 24 | 10 | 52 | |
alive at 3 years, no. (%) | 35 | 6 (16) | 29 (47) | |
alive at 5 years, no. (%) | 21 | 2 (5) | 19 (31) | |
Therapy protocol | ||||
AML-BFM-98 | 33 | 4 | 29 | |
HD 98 A | 15 | 4 | 11 | |
AMLCG | 12 | 5 | 7 | |
AML-SG 06-04 | 5 | 4 | 1 | |
AML-SG 07-04 | 5 | 3 | 2 | |
HOVON-SAKK AML-43 | 6 | 4 | 2 | |
supportive | 9 | 6 | 3 | |
unknown | 34 | 16 | 18 | |
Peripheral blood blasts, % median (range) | 65 (0-100) | 42 (0-95) | 66 (2-100) | 0.39 |
Bone marrow blasts, % median (range) | 85 (0-100) | 90 (25-98) | 85 (0-100) | 0.94 |
WBC, ×109/l median (range) | 33.7 (0.9-400) | 50.8 (2.6-222 | 32 (0.9-400) | 0.76 |